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Abstract 
Objective: To investigate the anxiolytic properties of a standardized extract of 
Sceletium tortuosum (trademarked―Zembrin®). 
Methods: Two studies utilized a placebo‐controlled, double‐blind, between‐subject 
experimental design to investigate the effects of a single dose of Sceletium tortuosum 
(25 mg, Zembrin®) on laboratory stress/anxiety responding in 20 young healthy 
volunteers. To elicit feelings of stress/anxiety, participants completed 20 min of the 
multitasking framework in study 1 and a 5‐min simulated public speaking task in study 2. 
Study 1 measured subjective experiences of mood at baseline, prestress induction, 
and poststress induction. Study 2 measured subjective experiences of anxiety and 
physiological indicators of stress (heart rate [HR] and galvanic skin response) at 
baseline, prestress induction, during stress induction, and poststress induction. 
Results: A series of analysis of covariances (baseline entered as the covariate) 
revealed no treatment effect in study 1; however, study 2 revealed subjective 
anxiety levels to be significantly lower in the Zembrin® group at the prestress 
induction point and a significant interaction between treatment and time on HR. 
Taken together, results indicate that a single dose of Zembrin® can ameliorate 
laboratory stress/anxiety responding in healthy volunteers. 
Conclusion: We provide the first tentative behavioral evidence to support the 
anxiolytic properties of Sceletium tortuosum (25 mg Zembrin®).  
K E Y W O R D S  
anxiety, anxiolytic, Sceletium tortuosum, stress, zembrin   
1 | INTRODUCTION 
Sceletium tortuosum (L.) N.E.Br. (Mesembryanthemaceae) is used by 
some tribal people of South Africa to reduce feelings of pain and hun-
ger, ameliorate stress, and enhance mental and physical performance 
(see review by Gericke & Viljoen, 2008). In western cultures, the pur-
ported therapeutic properties of Sceletium tortuosum have received 
limited scientific scrutiny; however, early research is promising. For 
example, Smith (2011) reported evidence of the anxiolytic properties 
of a low dose (5 mg/kg/day) but not a higher dose (20 mg/kg/day) of 
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Sceletium tortuosum on restraint‐induced anxiety in rats.1 Similarly, 
Hirabayashi, Ichikawa, Yoshi, Uchino, and Shimada (2004) demon-
strated reduced stress and anxiety in cats administered 10 mg/kg/day. 
More recently, a standardized extract of Sceletium tortuosum (trade-
marked as Zembrin®2) has accumulated a small body of evidence to 
support its safety, cognitive enhancing, anxiolytic properties, and 
identified potential biological mechanisms of action. With regards to 
safety, Nell, Siebert, Chellan, and Gericke (2013) demonstrated that 
both a low (8 mg) and a higher (25 mg) daily dose of Zembrin® ingested 
for 3 months were well tolerated in healthy participants. With regards 
to cognitive functioning, Dimpfel, Schombert, and Gericke (2016) 
demonstrated a dose‐dependent attenuation of spectral power 
following three acute doses of Zembrin® (2.5, 5.0, and 10.0 mg/kg) to 
adult Fischer rats, and Chiu et al. (2014) demonstrated, in older human 
adults, improved cognitive set flexibility and executive function 
following 3 weeks of daily consumption (25 mg Zembrin® per day). 
With regard to the anxiolytic effect of Zembrin®, two studies have 
identified potential biological mechanisms of action, the first demon-
strated Zembrin® to be a dual serotonin (5‐HT) transporter blocker and 
selective inhibitor of phosphodiesterase‐4 (Harvey, Young, Viljoen, & 
Gericke, 2011) and the second demonstrated a single 25 mg dose of 
Zembrin® could reduce anxiety‐related amygdala reactivity and 
attenuated amygdala–hypothalamus coupling in healthy young vol-
unteers 2 h postdose (Terburg et al., 2013). To the authors' knowledge, 
the anxiolytic effects of Zembrin® are yet to be investigated in a 
behavioral study; therefore, we report for the first time the results of 
two behavioral studies that directly tested the anxiolytic properties of 
Zembrin®. The first study also investigated two additional purported 
properties―the effects on feelings of hunger and memory perfor-
mance. We predict that Zembrin® will ameliorate stress/anxiety 
responding to acute laboratory stressors in healthy volunteers. 
2 | METHODS 
2.1 | Design 
Both studies utilized a placebo‐controlled, double‐blind, between‐ 
subject experimental design to investigate the anxiolytic effects of a 
single dose of Zembrin® (25 mg) in healthy volunteers. Study 1 
measured at baseline, prestress, and poststress induction. Study 2 
measured at baseline, prestress, during stress, and poststress induction. 
2.2 | Participants 
Study 1: Twenty (six male) healthy volunteers (mean age 19.6 years; 
SD 1.09; body mass index 20.87). Study 2: Twenty (11 male) healthy 
volunteers (mean age 21.3 years; SD 1.38). 
2.3 | Stress induction 
2.3.1 | Study 1: Multitasking framework 
The multi‐tasking framework (MTF; Purple Research Solutions) is a 
computerized stressor that reliably elicits cognitive demand, negative 
affect, stress, and anxiety (Scholey et al., 2009; Wetherell & Carter, 
2014). The MTF requires participants to attend to four tasks simul-
taneously that vary in terms of time pressure and/or difficulty; tasks 
are performance‐driven and demand is manipulated through 
instructing participants to achieve as high a score as they can. The 
current version consisted of four tasks (visual warning, mail alert, 
telephone entry, and maths), which required visual monitoring, 
accurate data entry, and mental arithmetic (for a detailed description 
of tasks, see Wetherell & Carter, 2014). 
2.3.2 | Study 2: Simulated public speaking task 
On the day of testing, participants were informed that they would 
be completing a 5‐min public speech to outline why they would be 
the most suitable applicant for a job of their choosing. Following a 
2‐min preparation period, participants stood in front of the 
researcher and performed their speech, the researcher gave no 
feedback, and participants were required to continue speaking for 
the duration of the task. Participants were also informed that their 
speech would be recorded and their performance considered by a 
panel of experts. 
2.4 | Outcome variables 
2.4.1 | Study 1 
Perceived Stress Scale (PSS; Cohen & Williamson, 1988): The PSS 
was used to measure perceptions of stress during the previous 
month. A higher score represents higher feelings of stress. 
Bond–Lader Visual Analogue Scales (Bond & Lader, 1974): A 
16‐item scale provides three mood dimensions as follows: (1) alert, 
(2) calm, and (3) content. The Bond–Lader was utilized to confirm 
stress induction and to assess any impact of treatment (scale uti-
lized in study 2 too). 
Visual Analogue Hunger Scale: A 100‐mm line anchored by “not 
hungry” to “very hungry.” Participants crossed the line at the point 
that best described their current feeling. A score of 0 (not hungry) to 
a score of 100 (very hungry). If results reveal a treatment effect on 
hunger, hunger will be included as a covariate. 
Immediate word recall: Two sets of 20 concrete nouns were 
created giving an A–B or B–A order. Each list was presented for 60 s, 
and participants were given 60 s for recall. 
The National Aeronautics and Space Administration task load 
index (NASA‐TLX; Hart & Staveland, 1988): The NASA‐TLX measures 
six workload domains. Three of which reflect the respondents 
perceived demands of the task (mental demand, physical demand, 
1However, numerous side effects were also reported for both doses.  
2The hydroethanolic extract of a select variety of Sceletium tortuosum plant standardized to 
contain 0.35%–0.45% total alkaloids: mesembrenone and mesembrenol ≥60%, and 
mesembrine <20%, HGH Inc. 
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and temporal demand), and three reflect the interaction between the 
task and the respondent (effort, perceived performance, and 
frustration). 
2.4.2 | Study 2 
State–Trait Anxiety Inventory (STAI; Spielberger, 2010): A 40‐item 
inventory split into two 20‐item sections. The first focuses on state 
anxiety whereas the second focuses upon trait anxiety. 
Visual Analogue Anxiety (VAa) Mood Scale (Wetherell, Craw, 
Smith, & Smith, 2017): A 10‐point scale anchored by “not at all” to 
“very anxious.” Participants marked the point that best describes 
their current feeling. A score of 0 (not at all feeling anxious) to a 
score of 10 (feeling very anxious). 
Biopac (Biopac Systems, Inc, Unit MP35): Heart rate (HR) and 
galvanic skin response (GSR) were utilized as physiological indicators 
of anxiety. 
2.5 | Procedure 
All participants provided written informed consent and attended 
between 8:30 a.m. and 10 a.m. Participants confirmed they had not 
consumed food or drink (water being an exception) since 8 p.m. and 
were randomly allocated placebo or Zembrin® treatment condition. 
Ethical approval was granted from the Department of Psychology at 
Northumbria University for study 1 and from the School of Social 
Science, Business and Law at Teesside University for study 2. Par-
ticipants completed task order as detailed in Figure 1. 
2.6 | Statistical analysis 
To confirm the absence of any group difference in “background” 
levels of stress/anxiety, baseline scores from the PSS (study 1) and 
STAI (study 2) were analyzed by one‐way between group analysis of 
variance (ANOVA). 
2.6.1 | Study 1 
Placebo data for the Bond–Lader was analyzed by one‐way repeated 
measures ANOVA to confirm stress induction. To explore treatment 
effects, each outcome measure was subject to an analysis of 
covariance (ANCOVA; baseline score was entered as the covariate). 
One‐way ANOVA was utilized for each domain of the NASA‐TLX (see 
Table 1 for means and SE). 
F I G U R E  1 Study protocol for study 1 and 
study 2. Dosage ¼ 25 mg Sceletium tortuosum 
(trademarked Zembrin®) or placebo. BL, 
Bond–Lader Visual Analogue Mood Scale; IWR, 
immediate word recall; PSS, Perceived Stress 
Scale; STAI(s), State–Trait Anxiety Inventory 
(state score); STAI (t), State–Trait Anxiety 
Inventory (trait score); TLX, the National 
Aeronautics and Space Administration task load 
index; VAa, Visual Analogue Anxiety Scale; VAh, 
Visual Analogue Hunger Scale   
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2.6.2 | Study 2 
Placebo data for the STAI(s), VAa scale, HR, and GSR were analyzed 
by one‐way repeated measures ANOVA to confirm stress induction. 
To explore treatment effects, each outcome was subject to ANCOVA 
(baseline score was entered as the covariate) (See Table 2 for means 
and SE). 
3 | RESULTS 
3.1 | Study 1 
3.1.1 | Background stress 
PSS: No significant difference between placebo and Zembrin® group 
(F(1,18) ¼ 0.76, p ¼ 0.785). 
3.1.2 | Stress induction 
A main effect of time on feelings of alertness (F(1,18) ¼5.74, p ¼0.012) 
and calmness (F(1,18) ¼ 9.87, p ¼ 0.001) confirm stress induction. 
3.1.3 | Effect of treatment 
No treatment effects observed on any outcome measure. 
3.2 | Study 2 
3.2.1 | Background anxiety 
STAI (trait): No difference between placebo and Zembrin® group 
(F(1,18) ¼ 0.105, p ¼ 0.750). 
T A B L E  1 Study 1: Means and SE for 
each outcome measure at baseline and 
each measurement point postdose    
Baseline Prestress Poststress 
Mean SE Mean SE Mean SE 
Perceived stress Zembrin®  22.2  2.8 ‐ ‐ ‐ ‐ 
Placebo  23.3  2.8 ‐ ‐ ‐ ‐ 
Mental demand Zembrin® ‐ ‐ ‐ ‐  64.1  4.65 
Placebo ‐ ‐ ‐ ‐  63.7  4.65 
Physical demand Zembrin® ‐ ‐ ‐ ‐  26.8  6.64 
Placebo ‐ ‐ ‐ ‐  22.3  6.64 
Temporal demand Zembrin® ‐ ‐ ‐ ‐  62.7  5.65 
Placebo ‐ ‐ ‐ ‐  49.6  5.65 
Effort Zembrin® ‐ ‐ ‐ ‐  61.5  4.40 
Placebo ‐ ‐ ‐ ‐  64.8  4.40 
Performance Zembrin® ‐ ‐ ‐ ‐  64.4  5.08 
Placebo ‐ ‐ ‐ ‐  63.3  5.08 
Frustration Zembrin® ‐ ‐ ‐ ‐  38.2  6.83 
Placebo ‐ ‐ ‐ ‐  31.3  6.83 
Hunger scale Zembrin®  43.5  7.44 ‐ ‐  58.95  2.48 
Placebo  69.5  2.72 ‐ ‐  59.04  2.30 
Word recall (number correct) Zembrin®  8.4  0.41  8.56  0.86 ‐ ‐ 
Placebo  9.9  0.53  9.91  0.81 ‐ ‐ 
Word recall (number error) Zembrin®  0.2  0.15  0.41  0.18 ‐ ‐ 
Placebo  0.5  0.22  0.33  0.17 ‐ ‐ 
Alert Zembrin®  53.18  4.40  61.67  2.97  66.88  3.29 
Placebo  53.84  4.12  61.42  2.97  62.84  3.29 
Calm Zembrin®  67.35  4.93  61.6  4.02  47.04  4.95 
Placebo  66.4  4.47  61.3  4.01  45.50  4.95 
Content Zembrin®  58.5  2.83  60.99  1.23  59.44  1.75 
Placebo  58.6  2.91  58.58  1.23  56.07  1.75 
Abbreviation: SE, standard error.  
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3.2.2 | Stress induction 
A trend toward a main effect of time on STAI(s) (F(2,14) ¼ 3.49, 
p ¼ 0.059) and HR (F(2,14) ¼ 3.325, p ¼ 0.06) coupled with a main 
effect of time on VA(a) (F(3,21) ¼ 3.23, p ¼ 0.043) confirmed stress 
induction. 
3.2.3 | Effects of treatment 
STAI (state): ANCOVA revealed a treatment � time interaction 
(F(1,17) ¼ 8.05, p ¼ 0.011). Post hoc analysis revealed a difference at 
prestress (p ¼ 0.009, d ¼ 1.01) with anxiety level significantly lower 
in the Zembrin® group (Figure 2). 
VAa scale: ANCOVA revealed a treatment � time interaction 
(F(2,34) ¼ 3.28, p ¼ 0.05). Post hoc analysis revealed a difference at 
prestress (p ¼ 0.024, d ¼ 1.11) with anxiety level being significantly 
lower in the Zembrin® group (Figure 2). 
HR: ANCOVA revealed a treatment � time interaction (F(1,17) ¼
6.08, p ¼ 0.025). The pattern of results demonstrates a physiological 
response to the stressor (increased HR) in placebo but not Zembrin® 
group (Figure 3). 
4 | DISCUSSION 
Results of the current studies provide the first tentative behavioral 
evidence to support the anxiolytic properties of Sceletium tortuosum 
(25 mg Zembrin®) but fail to replicate the previously reported 
enhancement of cognitive function. In the current studies, stress 
induction was confirmed in study 1 as participants reported 
increased subjective experience of alertness and decreased feelings 
of calmness following completion of the MTF (see Wetherell & 
Carter, 2014) and in study 2 by participants reporting elevated 
feelings of anxiety/stress and increased HR following completion of 
the simulated public speech task. With regard to the therapeutic 
properties of Sceletium tortuosum (Zembrin®), study 1 failed to show 
any effect of treatment on feelings stress or memory performance; 
however, study 2 demonstrated that Sceletium tortuosum (Zembrin®) 
ameliorated the anticipatory increase in subjective feelings of anxiety 
associated with the anticipated onset of a stressor and ameliorated 
increases in HR during a stressor. 
The lack of an anxiolytic effect in study 1 and on subjective 
measures at the mid and poststress testing points in study 2 could 
most parsimoniously be explained by our protocol. For example, 
despite both protocols inducting elevated feelings of stress, it could 
be that the stressor was too “mild” to allow a treatment effect to be 
observed in those subjective self‐report measures. For example, it is 
clear that our participants did not rate their reported anxiety 
greater than the half‐way point on the anxiety scale nor score more 
than half on the STAI(s). However, it should be noted that an effect 
was observed in the physiological measure. With regard to a lack of 
effect on cognitive function, we could interpret this result as the 
first evidence to suggest that Sceletium tortuosum (Zembrin®) has no 
impact on nonexecutive memory processing in healthy volunteers; 
however, we would advise some caution with this, as our primary 
aim was to investigate the anxiolytic properties and our research 
design was tailored toward this question and it is possible that again 
our lack of effect here can also be due to differences between our 
study and previous studies. For example, Terburg et al. (2013) uti-
lized a longer treatment regime, tested a different population (older 
adults), and assessed different cognitive functioning (i.e., executive 
functioning). We recommend that future studies consider using 
protocols that elicit stronger stress responses, for example, adding 
critical social evaluation to the MTF (e.g., Wetherell et al., 2017), or 
running a longer, and more challenging social evaluation paradigm 
T A B L E  2 Study 2: Means and SE for 
each outcome measure at baseline and 
each measurement point postdose    
Baseline Prestress Midstress Poststress 
Mean SE Mean SE Mean SE Mean SE 
STAI (trait) Zembrin®  39  2.75 ‐ ‐ ‐ ‐ ‐ ‐ 
Placebo  40.25  2.25 ‐ ‐ ‐ ‐ ‐ ‐ 
STAI (state) Zembrin®  30.58  2.06  33.96  2.81 ‐ ‐  37.82  2.22 
Placebo  35.38  2.20  44.43  3.48 ‐ ‐  35.88  2.75 
Anxiety scale Zembrin®  2.25  0.39  3.25  0.48  4.42  0.59  4.25  0.46 
Placebo  3.63  0.885  4.61  0.6  4.99  0.74  3.49  0.57 
HR (bpm) Zembrin®  87.1  5.19  91.8  2.09  90.5  2.27 ‐ ‐ 
Placebo  87.52  5.63  87.09  2.57  93.85  2.78 ‐ ‐ 
GSR Zembrin®  0.74  0.007  0.73  0.002  0.71  0.002 ‐ ‐ 
Placebo  0.71  0.88  0.75  0.002  0.74  0.002 ‐ ‐ 
Note: HR and GSR is average data at baseline (5 min), prestress (30 min), and midstress (5 min).  
Abbreviations: GSR, galvanic skin response; HR, heart rate; SE, standard error; STAI, State–Trait 
Anxiety Inventory.  
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to further our understanding of the anxiolytic effects of Sceletium 
tortuosum (Zembrin®). Future studies should also use more 
comprehensive cognitive assessment to investigate whether Scele-
tium tortuosum (Zembrin®) has any task/cognitive domain specificity 
of effect. 
We conclude that a single 25 mg dose of Sceletium tortuosum 
(Zembrin®) can ameliorate subjective and physiological indicators of 
stress/anxiety during a controlled laboratory stress protocol in young 
healthy volunteers. 
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